Intravitreal Clindamycin and Dexamethasone Combined with Systemic Oral Antitoxoplasma Therapy versus Intravitreal Therapy Alone in the Management of Toxoplasma Retinochoroiditis: A Retrospective Study

Table 1

BCVA (LogMAR) in both groups.

	Pretreatment	3rd month	6th month	12th month
Group I	1.08 ± 0.17	0.80 ± 0.19	0.72 ± 0.11	0.64 ± 0.18
Group II	1.03 ± 0.15	0.87 ± 0.21	0.75 ± 0.09	0.69 ± 0.17
value	0.8	0.7	0.5	0.8